Marshall Wace North America L.P. Sells 84,689 Shares of Agios Pharmaceuticals Inc (AGIO)

Marshall Wace North America L.P. trimmed its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 28.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 211,069 shares of the biopharmaceutical company’s stock after selling 84,689 shares during the period. Marshall Wace North America L.P.’s holdings in Agios Pharmaceuticals were worth $16,278,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Belpointe Asset Management LLC bought a new stake in Agios Pharmaceuticals in the third quarter worth approximately $888,000. Vanguard Group Inc. grew its position in Agios Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,251,439 shares of the biopharmaceutical company’s stock worth $327,871,000 after acquiring an additional 109,849 shares in the last quarter. Legal & General Group Plc grew its position in Agios Pharmaceuticals by 11.5% in the third quarter. Legal & General Group Plc now owns 26,464 shares of the biopharmaceutical company’s stock worth $2,041,000 after acquiring an additional 2,719 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 1.5% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 149,000 shares of the biopharmaceutical company’s stock worth $11,491,000 after buying an additional 2,202 shares during the period. Finally, Neuberger Berman Group LLC boosted its holdings in shares of Agios Pharmaceuticals by 1.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 343,391 shares of the biopharmaceutical company’s stock worth $26,482,000 after buying an additional 5,036 shares during the period. 95.33% of the stock is owned by institutional investors.

Shares of Agios Pharmaceuticals stock opened at $53.17 on Friday. Agios Pharmaceuticals Inc has a fifty-two week low of $51.37 and a fifty-two week high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The company had revenue of $15.20 million during the quarter, compared to the consensus estimate of $22.72 million. During the same period last year, the company earned ($1.59) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 33.8% on a year-over-year basis. Sell-side analysts forecast that Agios Pharmaceuticals Inc will post -6.12 EPS for the current fiscal year.

In other Agios Pharmaceuticals news, Director John Maraganore sold 13,555 shares of the stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $72.75, for a total value of $986,126.25. Following the completion of the sale, the director now directly owns 38,609 shares of the company’s stock, valued at approximately $2,808,804.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction on Monday, November 5th. The shares were sold at an average price of $69.69, for a total transaction of $209,070.00. Following the completion of the sale, the insider now directly owns 53,932 shares of the company’s stock, valued at $3,758,521.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 19,555 shares of company stock valued at $1,404,566. Insiders own 3.02% of the company’s stock.

Several analysts recently issued reports on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Thursday, November 1st. BidaskClub downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 15th. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Friday, November 16th. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, November 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday, September 5th. Six investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $96.27.

ILLEGAL ACTIVITY NOTICE: “Marshall Wace North America L.P. Sells 84,689 Shares of Agios Pharmaceuticals Inc (AGIO)” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/12/08/marshall-wace-north-america-l-p-sells-84689-shares-of-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Recommended Story: Stock Selection – What is cash flow?

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply